ACTRN12610000898055
Terminated
N/A
The utility of genomics and functional imaging to predict Irinotecan pharmacokinetics and pharmacodynamics: The PREDICT Irinotecan Study
Peter MacCallum Cancer Centre0 sites70 target enrollmentOctober 21, 2010
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- ocally advanced, recurrent or metastatic colorectal adenocarcinoma
- Sponsor
- Peter MacCallum Cancer Centre
- Enrollment
- 70
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically/cytologically confirmed locally advanced, recurrent or metastatic colorectal adenocarcinoma not amenable to surgery or radiation therapy with curative intent, eligible for first\-line or second\-line chemotherapy with Irinotecan\-5FU (FOLFIRI regimen or FOLFIRI\-Bevacizumab \[Avastin]); measurable or evaluable disease, adequate hepatic, bone marrow and renal function, Eastern Cooperative Oncology Group (ECOG) 2 or less, life expectancy greater than 12 weeks, written informed consent for the study and its associated procedures.
Exclusion Criteria
- •Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol or compromises the patient's ability to give informed consent.
- •Female patients who are pregnant or breast\-feeding.
- •Any unresolved toxicity greater than NCI\-CTC Grade 2 from previous anti\-cancer therapy, active liver disease (e.g. chronic active hepatitis, cirrhosis), known diagnosis of human immunodeficiency virus (HIV) infection or Gilbert’s syndrome, prior severe reaction of fluoropyrimidine therapy, known sensitivity to 5\-FU or deficit of dihydropyrimidine\-dehydrogenase (DPD)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
N/A
The use of non invasive methods to predict drug handling and toxicity of SunitinibMetastatic renal cell carcinoma (RCC)Metastatic Gastrointestinal Stromal Tumuor (GIST)Cancer - KidneyCancer - Other cancer typesACTRN12610000897066Peter MacCallum Cancer Centre70
Withdrawn
N/A
Bringing Neuroimaging and Genetics to the Clinic: A case for Attention-Deficit/Hyperactivity Disorder and Autism Spectrum DisorderAttention-Deficit/Hyperactivity DisorderDisorder 2) ASDAutisme Spectrum DisorderDisorder 1) ADHD10009841NL-OMON44585Radboud Universitair Medisch Centrum1,125
Recruiting
N/A
The utility of imaging findings using new sequence of MRI in brain tumorbrain tumorJPRN-UMIN000036504Tottori university60
Completed
N/A
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung canceron-Small Cell Lung CancerJPRN-UMIN000003675niversity of Tokushima20
Completed
N/A
Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR COPD).J44Other chronic obstructive pulmonary diseaseDRKS00005072niversitätsklinikum HeidelbergAbt. Für Diagnostsiche und Interventionelle Radiologie602